Opposite trends reported ANX2 as a suitable prognostic marker in HCC, renal (CRCC), colorectal and gastric carcinomas, where its expression negatively correlates with a favorable clinical outcome [85,93,96,100,101]. Here, ANXA2 is linked to hepatocellular carcinoma.